Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer

被引：1
|
作者：
Bolla, M. [1 ]
Fourneret, P. [1 ]
Descotes, J. -L. [2 ]
机构：
[1] CHU, Clin Univ Cancerol Radiotherapie, F-63011 Grenoble, France
[2] CHU, Clin Univ Urol, F-63011 Grenoble, France
来源：
BULLETIN DU CANCER | 2008年 / 95卷 / 12期
关键词：
high-risk prostate cancer; combination of external irradiation and androgen suppression;
D O I：
10.1684/bdc.2008.0755
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Treatment of high-risk prostate cancer-localized or locally advanced-is based on the combination of external irradiation and hormonal treatment by LHRH analogue (aLHRH) according to the results of phases III randomized trials RTOG and/or EORTC trials. These trials show a significant improvement of overall or specific survival. Localized prostate cancer require 6-month complete androgen blockade, while locally advanced prostate cancer need a long-term hormonal treatment for a duration ranging from 2,5 to 3 years. Some trials, which have a long follow-up show that the risk of cardiovascular death is not significantly increased by hormonal treatment.
引用
收藏
页码：1213 / 1218
页数：6
相关论文
共 50 条
  • [31] Laparoscopic radical prostatectomy for high-risk prostate cancer
    Di Benedetto, Antonina
    Soares, Ricardo
    Dovey, Zach
    Bott, Simon
    McGregor, Roy G.
    Eden, Christopher G.
    BJU INTERNATIONAL, 2015, 115 (05) : 780 - 786
  • [32] Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer
    Ravi, Praful
    Kwak, Lucia
    Devlies, Wout
    Xie, Wanling
    Chipidza, Fallon
    Yang, Xiaoyu
    Bubley, Glenn
    Kaplan, Irving
    Kibel, Adam S.
    Nguyen, Paul
    Taplin, Mary-Ellen
    PROSTATE, 2024, 84 (04) : 342 - 348
  • [33] Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer
    Muralidhar, Vinayak
    Xiang, Michael
    Orio, Peter F., III
    Martin, Neil E.
    Beard, Clair J.
    Feng, Felix Y.
    Hoffman, Karen E.
    Nguyen, Paul L.
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2016, 8 (01) : 1 - 6
  • [34] The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis
    Wang, Zhipeng
    Ni, Yuchao
    Chen, Junru
    Sun, Guangxi
    Zhang, Xingming
    Zhao, Jinge
    Zhu, Xudong
    Zhang, Haoran
    Zhu, Sha
    Dai, Jindong
    Shen, Pengfei
    Zeng, Hao
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
  • [35] Oncological control in high-risk prostate cancer after radical prostatectomy and salvage radiotherapy compared to radiotherapy plus primary hormone therapy
    Cano-Velasco, J.
    Herranz-Amo, F.
    Barbas-Bernardos, G.
    Polanco-Pujol, L.
    Verdu-Tartajo, F.
    Lledo-Garcia, E.
    Hernandez-Fernandez, C.
    ACTAS UROLOGICAS ESPANOLAS, 2019, 43 (04): : 190 - 197
  • [36] Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis
    Alessia Guarneri
    Angela Botticella
    Andrea Riccardo Filippi
    Andrea Ruggieri
    Cristina Piva
    Fernando Munoz
    Riccardo Ragona
    Paolo Gontero
    Umberto Ricardi
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1141 - 1147
  • [37] The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis
    Zhipeng Wang
    Yuchao Ni
    Junru Chen
    Guangxi Sun
    Xingming Zhang
    Jinge Zhao
    Xudong Zhu
    Haoran Zhang
    Sha Zhu
    Jindong Dai
    Pengfei Shen
    Hao Zeng
    World Journal of Surgical Oncology, 18
  • [38] High-Risk Prostate Cancer: From Definition to Contemporary Management
    Bastian, Patrick J.
    Boorjian, Stephen A.
    Bossi, Alberto
    Briganti, Alberto
    Heidenreich, Axel
    Freedland, Stephen J.
    Montorsi, Francesco
    Roach, Mack, III
    Schroder, Fritz
    van Poppel, Hein
    Stief, Christian G.
    Stephenson, Andrew J.
    Zelefsky, Michael J.
    EUROPEAN UROLOGY, 2012, 61 (06) : 1096 - 1106
  • [39] The multi-disciplinary management of high-risk prostate cancer
    Picard, Jonathan C.
    Golshayan, Ali-Reza
    Marshall, David T.
    Opfermann, Krisha J.
    Keane, Thomas E.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2012, 30 (01) : 3 - 15
  • [40] Current and emerging therapies for localized high-risk prostate cancer
    Moris, Lisa
    Devos, Gaetan
    Van den Broeck, Thomas
    Milonas, Daimantas
    Albersen, Maarten
    Berghen, Charlien
    De Meerleer, Gert
    Devlies, Wout
    Everaerts, Wouter
    Gevaert, Thomas
    Van Poppel, Hendrik
    Claessens, Frank
    Joniau, Steven
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (03) : 267 - 282
12345